Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Pik3cdem1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Pik3cdem1flox/Cya

Common Name
Pik3cd-flox
Product ID
S-CKO-04276
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-18707-Pik3cd-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Pik3cd-flox Mouse (Catalog S-CKO-04276) were purchased from Cyagen.”
cKO Models
mTOR signaling pathway
AMPK signaling pathway
ErbB signaling pathway
JAK-STAT signaling pathway
PI3K-Akt signaling pathway
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
mTOR signaling pathway
AMPK signaling pathway
ErbB signaling pathway
JAK-STAT signaling pathway
PI3K-Akt signaling pathway
Basic Information
Strain Name
Pik3cd-flox
Strain ID
CKOCMP-18707-Pik3cd-B6J-VA
Gene Name
Pik3cd
Product ID
S-CKO-04276
Gene Alias
p110delta, 2410099E07Rik, 2610208K16Rik
Background
C57BL/6JCya
Gene Full Name
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
Modification
Conditional knockout
NCBI ID
18707 (Mouse)
Phenotype
MGI:1098211
Chromosome
Chr 4 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000105690
NCBI Transcript ID
NM_001164049
Target Region
Exon 12~20
Size of Effective Region
~2.9 kb
Overview of Gene Research
Pik3cd, encoding the catalytic p110δ subunit of phosphoinositide 3-kinase (PI3K), is crucial in the PI3K-AKT-mechanistic target of rapamycin pathway. This pathway is involved in various biological processes such as cell growth, differentiation, and immune response [2,7].

In breast carcinoma, Pik3cd expression is associated with prognosis, epithelial-mesenchymal transition (EMT), and tumor immune infiltration. In gastric carcinoma, its overexpression promotes tumor development, and genetic silencing retards proliferation and migration both in vitro and in vivo [1,4]. In glioblastoma, knockout of Pik3cd in cell lines reduces migration, invasion, and colony-forming ability, and negates tumorigenesis in nude mice, potentially acting through cytoskeletal proteins PAK3 and PLEK2 [5]. In colorectal cancer, overexpression of Pik3cd promotes cell growth, migration, and invasion by activating AKT/GSK-3β/β-catenin signaling [6]. In abnormal retinal angiogenesis, editing genomic Pik3cd in a mouse model significantly reduces pathological angiogenesis [3]. In addition, in diabetic retinopathy, Pik3cd is involved in promoting microvascular endothelial cell proliferation, migration, and angiogenesis [8].

In conclusion, Pik3cd plays essential roles in multiple biological processes and disease conditions. Studies using gene knockout models, such as in glioblastoma and abnormal retinal angiogenesis mouse models, have revealed its role in tumorigenesis and angiogenesis. These findings suggest that Pik3cd could be a potential therapeutic target for various diseases including carcinomas, glioblastoma, and diseases related to abnormal angiogenesis [3,5].

References:
1. He, Wenxing, Zhang, Haoyi, Cheng, Hong, Wen, Jianfeng, Li, Dongmei. 2023. PIK3CD correlates with prognosis, epithelial-mesenchymal transition and tumor immune infiltration in breast carcinoma. In Discover oncology, 14, 187. doi:10.1007/s12672-023-00805-0. https://pubmed.ncbi.nlm.nih.gov/37861728/
2. Lucas, Carrie L, Chandra, Anita, Nejentsev, Sergey, Condliffe, Alison M, Okkenhaug, Klaus. 2016. PI3Kδ and primary immunodeficiencies. In Nature reviews. Immunology, 16, 702-714. doi:10.1038/nri.2016.93. https://pubmed.ncbi.nlm.nih.gov/27616589/
3. Wu, Wenyi, Ma, Gaoen, Qi, Hui, Zhang, Shaochong, Lei, Hetian. . Genome Editing of Pik3cd Impedes Abnormal Retinal Angiogenesis. In Human gene therapy, 34, 30-41. doi:10.1089/hum.2022.079. https://pubmed.ncbi.nlm.nih.gov/36515172/
4. Hu, Qingqing, Dou, Ning, Wu, Qiong, Li, Yandong, Chen, Jingde. 2024. JAK3/STAT5 signaling-triggered upregulation of PIK3CD contributes to gastric carcinoma development. In Journal of cell communication and signaling, 18, e12017. doi:10.1002/ccs3.12017. https://pubmed.ncbi.nlm.nih.gov/38545256/
5. Shao, Wei, Azam, Zulfikar, Guo, Jintao, To, Shing Shun Tony. 2022. Oncogenic potential of PIK3CD in glioblastoma is exerted through cytoskeletal proteins PAK3 and PLEK2. In Laboratory investigation; a journal of technical methods and pathology, 102, 1314-1322. doi:10.1038/s41374-022-00821-8. https://pubmed.ncbi.nlm.nih.gov/35851857/
6. Chen, Jing-Song, Huang, Jiong-Qiang, Luo, Bing, Wen, Guang-Ming, Zhong, Jian-Feng. 2019. PIK3CD induces cell growth and invasion by activating AKT/GSK-3β/β-catenin signaling in colorectal cancer. In Cancer science, 110, 997-1011. doi:10.1111/cas.13931. https://pubmed.ncbi.nlm.nih.gov/30618098/
7. Edwards, Emily S J, Bier, Julia, Cole, Theresa S, Uzel, Gulbu, Tangye, Stuart G. 2018. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity. In The Journal of allergy and clinical immunology, 143, 276-291.e6. doi:10.1016/j.jaci.2018.04.030. https://pubmed.ncbi.nlm.nih.gov/29800648/
8. He, Fu-Tao, Fu, Xiao-Lin, Li, Mo-Han, Fu, Chun-Yan, Chen, Jian-Zhi. 2023. USP14 Regulates ATF2/PIK3CD Axis to Promote Microvascular Endothelial Cell Proliferation, Migration, and Angiogenesis in Diabetic Retinopathy. In Biochemical genetics, 61, 2076-2091. doi:10.1007/s10528-023-10358-0. https://pubmed.ncbi.nlm.nih.gov/36939972/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research